Search Results 1981-1990 of 19694 for Hemoglobin

1. A Study To Evaluate The Efficacy And Safety Of Obinutuzumab In Patients With ISN/RPS 2003 Class III Or IV Lupus Nephritis - Mayo Clinic

   Hemoglobin < 7 g/dL, unless caused by autoimmune hemolytic anemia resulting from SLE. Platelet count < 25,000/µL. Positive serum human chorionic ...

2. A Study of Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma - Mayo Clinic

   Bone Marrow: Absolute neutrophil count (ANC) ≥ 1,500/mm^3; Platelets ≥ 100,000/mm^3; Hemoglobin ≥ 9.0 g/dL;; Renal function: Serum creatinine ≤ 1.5 X ...

3. Phase 2a Open-Label Pilot Study Of VTX2735 In Recurrent Pericarditis - Mayo Clinic

   Hemoglobin < 9 g/dL f. AST or ALT ≥ 2.0 × ULN; Total bilirubin level > 1.5 × ULN unless the participant has been diagnosed with Gilberts' disease and this ...

4. Neurosurgery - Clinical trials

   In addition to belonging to one of these 16 subcohorts, patients will be required to have bloodwork demonstrating a blood hemoglobin ≥ 10 g/dL, a ...

5. Neurosurgery - Clinical trials

   In addition to belonging to one of these 16 subcohorts, patients will be required to have bloodwork demonstrating a blood hemoglobin ≥ 10 g/dL, a ...

6. Filgotinib In The Induction And Maintenance Of Remission In Adults With Moderately To Severely Active Ulcerative Colitis - Mayo Clinic

   Hemoglobin ≥ 8 g/dL;; Absolute neutrophil count (ANC) ≥ 1.5 × 109/L (1,500/mm3);; Platelets ≥ 100 × 109/L;; White blood cells (WBC) ≥ 3.0 x 109/L;; Absolute ...

7. GATE1: A Multicenter Phase II Study Of Pirtobrutinib, Rituximab And Venetoclax Combination Therapy For Patients With Previously Untreated Mantle Cell Lymphoma - Mayo Clinic

   * Hemoglobin ≥ 8.0 g/dL without transfusion support * Prothrombin (PT) or international normalized ratio (INR) ≤ 1.5 × upper normal limit (ULN)

8. Alternate Doses and Dosing Schedules of Belantamab Mafodotin for the Treatment of Triple-Class Recurrent and/or Refractory Multiple Myeloma - Mayo Clinic

   - Hemoglobin >= 8.0 g/dL (=< 28 days prior to registration) - Without growth factor support, blood transfusion, or platelet stimulating agents for the past ...

9. A pivotal study of derazantinib in patients with inoperable or advanced intrahepatic cholangiocarcinoma and FGFR2 gene fusions or FGFR2 gene mutations or amplifications - Mayo Clinic

   Hemoglobin (Hgb) ≥ 9.0 g/dL;; Absolute neutrophil count (ANC) ≥ 1.5 × 10^9/L;; Platelet count ≥ 75 × 10^9/L;; International normalized ratio (INR) 0.8 to ...

10. Olaparib or Cediranib Maleate and Olaparib Compared With Standard Platinum-Based Chemotherapy in Treating Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer - Mayo Clinic

    Hemoglobin >= 10 g/dL; Creatinine =< the institutional upper limit of normal (ULN) OR creatinine clearance >= 60 mL/min/1.73 m^2 for patients with creatinine ...